Latest news with #SteveHarper
Yahoo
2 days ago
- Business
- Yahoo
Lancaster voters to see another sales tax referendum for roads plan. What we know
Lancaster County is a step closer to a new 1% sales tax to fund roads, but only if voters approve it this time. Lancaster County Council voted 5-2 on Monday to put a sales-tax-for-roads proposal back on the ballot this November. It'll take two more council votes to finalize the decision. Last November, more than 52% of county voters rejected a new tax for roads. That proposal would've taxed sales for up to 15 years and generated up to $405 million. Now, the county would ask voters for a tax that would last 10 years or generate $253 million. All council members want the road funding option, but Councilman Steve Harper and Councilman Billy Mosteller had concerns about the timing. 'This is much needed,' Harper said. 'My biggest concern is eight months ago, my voters told me no on this. I just think it's one year too soon.' Mosteller has concerns that if county voters turn down the proposal this fall, it might never pass. County officials see the sales tax as a committed funding source for large road projects that doesn't exist there now, similar to the voter-approved Pennies for Progress program in York County. 'Our citizens said no in November, and it needs more time for planning and educating our citizens on what council is trying to do,' Mosteller said. With Lancaster County one of the highest-growth areas in the Charlotte and Southeast regions, though, other council members have concerns about waiting. Nearly half of voters last November voted for the new tax. 'They've been waiting on something like this for a very long time,' said Councilman Stuart Graham. The sales tax rate in Lancaster County would increase from 8% to 9% if voters approve the ballot question in November. The proposed road improvement list could change before the ballot is approved, but the $253 million figure wouldn't. The plan would put $98 million to major road widening like U.S. 521 and Henry Harris Road. Nine intersection improvements would cost $38 million. Another $20 million would go to four roundabouts, two of them on Shiloh Unity Road. The tax would generate $5 million for administration costs and $2 million for greenways and sidewalks. 'A program like this we would probably have to add on some more staff and have a manager of the project,' said Jeff Catoe, county public works director. The remaining $90 million would go to repaving. A proposed list has portions of 40 county or state roads, 51 in Lancaster, 32 in Kershaw and eight in Heath Springs. The ballot would have two related questions. One would ask voters if the county could charge the new tax, and the other would ask if the county could borrow money against that tax revenue if it passes. Borrowing would allow road work to start sooner than waiting for 10 years of tax collections would. November's ballot also would state which roads would be improved if the tax passes. Last fall, there were separate road plans that the tax would cover, but it wasn't attached to the ballot. 'We tried to be much more overt about what the projects are,' said County Administrator Dennis Marstall. A new tax campaign will have to overcome a stark split in support. Both the roads and a separate school bond that failed last November had proposals that focused heavily on high-growth Indian Land. The panhandle part of U.S. 521 got the bulk of attention, and would again this November. All 11 voting precincts north of Van Wyck opted to approve a new tax for roads last year. All 25 precincts south of Van Wyck voted against it. In the northernmost precinct, more than 63% voted in favor. In the three southernmost precincts, 67%-70% voted against. With a presidential election last year, voter turnout was much higher than it's likely to be this fall. Nearly 55,000 ballots were cast in November, for a nearly 80% voter turnout. The county continues to look for other road funding options in Indian Land. A recent application to the South Carolina Transportation Infrastructure Bank asks for $40 million. The new road tax, county officials say, could provide money the county could use to attract other funds through grant matches or partnerships.
Malaysian Reserve
21-05-2025
- Business
- Malaysian Reserve
More Than 75 Emerging Biotechs Use Veeva Basics Across Clinical, Regulatory, and Quality
Delivers pre-configured, pre-validated software that can scale with the needs of fast-growing companies BARCELONA, Spain, May 20, 2025 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that Veeva Basics is being used by more than 75 biotechs to gain efficiency and reduce costs across clinical, regulatory, and quality. With standardized applications, biotechs are going live with industry-leading software in weeks and gaining a system that can scale as they expand their business. The rapid adoption of Veeva Basics signals a shift from disparate entry-level tools toward complete, best-of-breed solutions that can support biotechs today and as they grow. Designed specifically for fast-growing companies, Veeva Basics provides pre-configured and pre-validated solutions. This enables fast deployment and adoption regardless of company size. With clinical, regulatory, and quality solutions available, Veeva is adding two new applications for biotechs: Veeva CTMS Basics for clinical trial management, including milestones, monitoring, enrollment, issue resolution, and site communications. Veeva Submissions Publishing Basics for building, publishing, and transmitting regulatory submissions in a single system. 'More biotechs are adopting Veeva Basics in North America and Europe, driving savings in time, cost, and effort,' said Steve Harper, general manager of Veeva Basics. 'Our approach to deliver pre-configured and pre-validated solutions that can go live quickly is gaining momentum, and we're adding new clinical and regulatory solutions to meet the needs of high-growth companies. With complete cloud applications, biotechs can ensure they are always current and benefit from the latest features.' Veeva CTMS Basics and Submissions Publishing Basics are available today in North America and Europe. Built on the proven Vault Platform, Veeva Basics applications allow customers to scale their technology infrastructure as they grow. For more on Veeva Basics, visit What biotechs are saying about Veeva Basics: 'I believe Veeva Basics is a game changer, giving smaller biotech companies access to the same modern and connected applications that are typically only available to larger organizations,' said Ian Hodgson, Ph.D., chief operating officer at Corbus Pharmaceuticals, Inc. 'As our company continues to grow, I am confident that Veeva's platform can scale with us and help ensure we remain up to date as regulatory requirements evolve.' 'As we expand our studies to a larger scale, Veeva eTMF Basics gives us more control of our data and process to ensure inspection readiness,' said Joe Thornton, associate director, clinical operations at Scancell. 'Having an industry-leading solution with pre-configured best practices as our foundation for trials will help drive speed and innovation as we continue to develop novel immunotherapies.' 'The global support and training provided with Veeva Basics helps us gain maximum value from Veeva's industry solution,' said Rebecca Deng, Ph.D., associate director, regulatory affairs and QA systems at Terns Pharmaceuticals. 'With a simple path to go live and validation, Veeva Basics has delivered significant time and resource savings.' About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services, including certain of our new solutions and applications that are still under development or not generally available. These statements are based on our current expectations. Actual results, availability, and any future events relating to these products and services could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at Contact: Jeremy WhittakerVeeva Systems+ View original content:
Associated Press
20-05-2025
- Business
- Associated Press
Spotline V-Assure Platform Enables Pre-Validation for Veeva Basics Releases
SAN JOSE, Calif., May 20, 2025 /PRNewswire/ -- Spotline, Inc., a Veeva-certified product, services, and AI partner, today announced that Veeva Systems is using its V-Assure platform to enable faster, pre-validated software releases for Veeva Basics—the pre-configured solution designed to help emerging biotechs achieve rapid deployment and built-in GxP compliance. Veeva used Spotline's V-Assure platform to accelerate the delivery of the last three releases of Veeva Basics for clinical, regulatory, and quality. V-Assure automated testing for these applications, providing emerging biotech customers with documentation to support the Basics Production Qualification. How Spotline Supports Veeva Basics' Mission for Biotech Speed and Compliance To help Veeva deliver Veeva Basics efficiently as a turnkey application, Spotline: This proactive, automation-first approach helped ensure that every release was audit- and inspection-ready to support accelerated development and release management of Veeva Basics. 'By using Spotline's V-Assure testing platform, we can deliver complete qualification documentation across our Veeva Basics applications,' said Steve Harper, General Manager of Veeva Basics. 'Automating testing helps us to move faster and provide testing and documentation on behalf of our customers. This saves time and effort while accelerating application delivery for emerging biotech.' Automated Validation Across Veeva Basics Applications With Spotline's V-Assure one-touch automated testing within each release cycle, Veeva successfully delivered audit- and inspection-ready validation documentation for its Veeva Basics applications in clinical, regulatory, and quality. Through the validation process, Veeva automated more than 500 test case executions across its Veeva Basics applications. 'Supporting the Veeva Basics team through three major releases has showcased how automated validation—when done right—can deliver speed and reliability,' said Sid Sahoo, CEO of Spotline, Inc. 'V-Assure is helping life sciences organizations modernize their validation processes and unlock faster adoption of compliant solutions.' Meet Us at the Veeva R&D and Quality Summits Spotline will demonstrate the latest version of V-Assure, including its enhanced integrations with Veeva Validation Management, at the upcoming Veeva R&D and Quality Summits in Europe and the U.S. Attendees are encouraged to schedule a demo at to explore how V-Assure can transform their validation operations. About Spotline Inc. Spotline Inc. is a Veeva-certified partner delivering innovative validation, automation, and integration solutions for life sciences. Through products like V-Assure, Spotline enables biotech and pharmaceutical companies to accelerate compliance, reduce risk, and focus on strategic innovation. For more information about Spotline, please visit Contact Info Jeff Andrist Spotline Inc. Email: [email protected] View original content to download multimedia: SOURCE Spotline, Inc.
Yahoo
20-05-2025
- Business
- Yahoo
More Than 75 Emerging Biotechs Use Veeva Basics Across Clinical, Regulatory, and Quality
Delivers pre-configured, pre-validated software that can scale with the needs of fast-growing companies PLEASANTON, Calif., May 20, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva Basics is being used by more than 75 biotechs to gain efficiency and reduce costs across clinical, regulatory, and quality. With standardized applications, biotechs are going live with industry-leading software in weeks and gaining a system that can scale as they expand their business. The rapid adoption of Veeva Basics signals a shift from disparate entry-level tools toward complete, best-of-breed solutions that can support biotechs today and as they grow. Designed specifically for fast-growing companies, Veeva Basics provides pre-configured and pre-validated solutions. This enables fast deployment and adoption regardless of company size. With clinical, regulatory, and quality solutions available, Veeva is adding two new applications for biotechs: Veeva CTMS Basics for clinical trial management, including milestones, monitoring, enrollment, issue resolution, and site communications. Veeva Submissions Publishing Basics for building, publishing, and transmitting regulatory submissions in a single system. "More biotechs are adopting Veeva Basics in North America and Europe, driving savings in time, cost, and effort," said Steve Harper, general manager of Veeva Basics. "Our approach to deliver pre-configured and pre-validated solutions that can go live quickly is gaining momentum, and we're adding new clinical and regulatory solutions to meet the needs of high-growth companies. With complete cloud applications, biotechs can ensure they are always current and benefit from the latest features." Veeva CTMS Basics and Submissions Publishing Basics are available today in North America and Europe. Built on the proven Vault Platform, Veeva Basics applications allow customers to scale their technology infrastructure as they grow. For more on Veeva Basics, visit What biotechs are saying about Veeva Basics:"I believe Veeva Basics is a game changer, giving smaller biotech companies access to the same modern and connected applications that are typically only available to larger organizations," said Ian Hodgson, Ph.D., chief operating officer at Corbus Pharmaceuticals, Inc. "As our company continues to grow, I am confident that Veeva's platform can scale with us and help ensure we remain up to date as regulatory requirements evolve." "As we expand our studies to a larger scale, Veeva eTMF Basics gives us more control of our data and process to ensure inspection readiness," said Joe Thornton, associate director, clinical operations at Scancell. "Having an industry-leading solution with pre-configured best practices as our foundation for trials will help drive speed and innovation as we continue to develop novel immunotherapies." "The global support and training provided with Veeva Basics helps us gain maximum value from Veeva's industry solution," said Rebecca Deng, Ph.D., associate director, regulatory affairs and QA systems at Terns Pharmaceuticals. "With a simple path to go live and validation, Veeva Basics has delivered significant time and resource savings." About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services, including certain of our new solutions and applications that are still under development or not generally available. These statements are based on our current expectations. Actual results, availability, and any future events relating to these products and services could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at Contact: Deivis MercadoVeeva View original content to download multimedia: SOURCE Veeva Systems Sign in to access your portfolio
Yahoo
24-02-2025
- Sport
- Yahoo
United's Under-12s win Premier League International Futsal Finals
The young Magpies, who qualified for the competition from the Northern Regionals, advanced into the semi-final stages on Saturday after finishing in top spot of the eight-team group, accruing 19 points in the process. Newcastle's youngsters won six of their seven unbeaten group matches, scoring a total of 26 goals in the process and beat the likes of Manchester City, Chelsea, Crystal Palace, West Ham United, Aston Villa and Stoke City as well as holding FC Barcelona to a 2-2 draw. United reached the final on Sunday after an entertaining 6-4 win against Chelsea to book a final showdown with West Ham, who they had beaten 3-2 in their group fixture, before lifting the trophy in style after a thrilling 8-2 win. Newcastle United Academy Director, Steve Harper, said: "Everyone at the Academy is incredibly proud of this group of players and staff. "To win it last year (at U11 level) was very special but to defend it against such a high calibre of opposition from this country and abroad is incredible. "Well done to all of the boys and also to lead coach Michael Pedley and the staff."
